Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23741993 | 0.97 | MEN1 (0.33) | MEN1KMT2ACOMT | |
| SCHEMBL22628373 | 0.97 | MEN1 (0.33) | MEN1KMT2ACOMT | |
| SCHEMBL21217055 | 0.97 | MEN1 (0.33) | MEN1KMT2ACOMT | |
| SCHEMBL21946577 | 0.97 | KMT2A (0.34) | MEN1KMT2ACOMT | |
| SCHEMBL21210837 | 0.94 | MEN1 (0.31) | MEN1KMT2ACOMT | |
| SCHEMBL26774679 | 0.90 | MEN1 (0.33) | MEN1KMT2ACOMT | |
| SCHEMBL23742021 | 0.83 | MEN1 (0.33) | MEN1KMT2ACOMT | |
| SCHEMBL24974206 | 0.82 | GPR84 (0.35) | MEN1KMT2A | |
| SCHEMBL21023553 | 0.82 | GPR84 (0.35) | MEN1KMT2A | |
| SCHEMBL24908204 | 0.81 | MEN1 (0.33) | MEN1KMT2ACOMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025877-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-01-25 | — | — | US | disclosed |
| US-20210246117-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246117-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SCNN1G | MEN1 4125/4885KMT2A 4802/4885COMT 3306/4885 |
| US-20240025877-A1 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SCNN1G | MEN1 4316/4885KMT2A 4813/4885COMT 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.